ClinicalTrials.gg
CompletedNCT07099313Updated Nov 12, 2026

Association of Prophylactic Treatment With Treatment Burden and Psychosocial Variables in Patients With Hemophilia

An observational study in Hemophilia, sponsored by Investigación en Hemofilia y Fisioterapia. Completed at 1 site in Spain. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Investigación en Hemofilia y Fisioterapia · Observational

How we know

Updated Nov 12, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
114
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Hemophilia A by Investigación en Hemofilia y Fisioterapia — 5 open to participants now, 6 under way, none of them phase 3. Hemophilia A · Investigación en Hemofilia y Fisioterapia.

Started
2025
with 3 others
Observational
9 of 21
2 open now
Registered
16th of 21
by date

Among the 21 studies in Hemophilia A by Investigación en Hemofilia y Fisioterapia, this one is one of 4 that started in 2025, is one of 9 observational ones, and was the 16th registered.

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

5 of the 21 studies in Hemophilia A by Investigación en Hemofilia y Fisioterapia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hemophilia A by Investigación en Hemofilia y Fisioterapia, or all of them as a file.
02

Study summary

Introduction: Hemophilia is a congenital coagulopathy characterised by recurrent haemarthrosis, leading to chronic arthropathy and functional impairment. Prophylactic treatment with extended half-life (EHL) or short half-life (SHL) clotting factor concentrates is the most effective strategy for preventing these episodes. EHL products have demonstrated haemostatic efficacy, with a lower frequency of infusions, potentially reducing the treatment burden, although their psychosocial impact has not yet been sufficiently explored.

Objectives: To evaluate the association between perceived treatment burden and psychosocial variables such as self-efficacy, adherence, sleep quality and health locus of control, depending on the type of treatment received (EHL or SHL).

Methods. Multicentre, ambispective cohort study. A total of 114 patients with haemophilia A or B undergoing EHL or SHL prophylactic treatment will be included. The primary variable will be treatment burden (Treatment Burden Questionnaire). Secondary variables will be perceived self-efficacy (General Self-Efficacy Scale), adherence (Torres scale), sleep quality (Pittsburgh Sleep Quality Index), treatment adherence (Torres Questionnaire) and health locus of control (Multidimensional Health Locus of Control). Potential confounding variables will include sociodemographic data (age, educational level, living arrangements) and clinical data (number of weekly infusions, type of hospital).

Expected results: Patients treated with extended-half-life products are expected to report lower treatment burden, higher self-efficacy and better sleep quality, regardless of sociodemographic or clinical factors.

03

Conditions studied

  • Hemophilia

Browse trials for

Keywords

  • Hemophilia
  • Clotting factor concentrates
  • Treatment burden
  • Perceived self-efficacy
  • Adherence
  • Locus of control
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with hemophilia A or B, undergoing prophylactic treatment with clotting factor concentrates.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 18 years of age.
  • Patients with a medical diagnosis of hemophilia A or B.
  • Patients who, regardless of disease phenotype (mild, moderate or severe), are receiving prophylactic treatment with recombinant or plasma clotting factor concentrates, either short half-life or extended half-life.
  • Patients must have maintained the same treatment regimen (SHL or EHL) continuously for at least six months prior to participation.

Exclusion criteria

Exclusion Criteria:

  • Patients who have developed inhibitors or antibodies to FVIII or FIX concentrates.
  • People with a concomitant diagnosis of other serious or disabling chronic diseases (neurological, oncological, severe psychiatric or rheumatological) that may interfere with the perceived burden of treatment, sleep quality, functionality or perception of self-efficacy.
  • Patients with cognitive, linguistic or sensory impairments that prevent them from correctly understanding and completing the questionnaires.
  • Patients who are participating in clinical trials or intensive monitoring programmes that may alter their perception of the treatment and generate biases in the evaluation.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
114 participants (actual)
Patient registry
No

Groups and cohorts

  • Observational group

    Patients diagnosed with hemophilia A or B, undergoing prophylactic treatment with short half-life (SHL) and extended half-life (EHL) clotting factor concentrates.

06

What researchers measure

Primary outcomes

  1. Assessment of treatment burden at the time of the study.

    Treatment burden will be assessed using the Spanish version of the Treatment Burden Questionnaire (TBQ). This self-administered multidimensional instrument consists of 15 items that measure the perceived burden of treatment in dimensions such as time spent, emotional impact, physical effort, medical coordination, and interference with daily life. Each item is scored on a Likert scale from 0 (no burden) to 10 (extreme burden). A total score is obtained, with higher values indicating greater perceived burden. This version has demonstrated good internal reliability in the Spanish chronic population (Cronbach's α = 0.89).

    Time frame: Screening visit.

Secondary outcomes

  1. Assessment of perceived self-efficacy in health at the time of the study.

    Perceived self-efficacy in health will be measured using the Spanish version of the General Self-Efficacy Scale (GSE). This questionnaire consists of 10 items with a 4-point Likert scale (1 = strongly disagree to 4 = strongly agree). It assesses the individual's general belief in their ability to cope with difficulties and manage their health. The total score ranges from 10 to 40, with higher values indicating greater self-efficacy. The scale has shown good internal consistency (Cronbach's α = 0.87) in the Spanish population.

    Time frame: Screening visit.

  2. Assessment of adherence to treatment at the time of the study.

    Adherence to treatment will be assessed using the Torres scale. This structured self-report, specific for patients with hemophilia, includes 25 items, grouped into 5 dimensions: awareness of the disease, knowledge of sequelae, treatment difficulties, doctor-patient relationship, and treatment of bleeding episodes. This scale has proven to be valid and reliable for assessing adherence in these patients, with good internal consistency across all dimensions. The total score ranges from 0 to 100, with higher values indicating poorer adherence.

    Time frame: Screening visit.

  3. Assessment of sleep quality at the time of the study.

    Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI) in its validated Spanish version. This self-administered questionnaire assesses sleep quality over the last month through 19 items grouped into seven components (latency, duration, efficiency, disturbances, medication use, daytime dysfunction, and subjective sleep quality). Each component is scored from 0 to 3, generating an overall score from 0 to 21, where a score \>5 indicates poor sleep quality. Its test-retest reliability and internal consistency have been adequate (Cronbach's α = 0.81).

    Time frame: Screening visit.

  4. Assessment of health locus of control at the time of the study.

    Health locus of control will be measured using the Spanish version of the Multidimensional Health Locus of Control Form C (MHLC-C). This scale consists of 18 items that assess the extent to which people attribute control of their health to internal, medical or random factors. It consists of three subscales of 6 items each, scored on a scale from 1 (total disagreement) to 6 (total agreement). Each subscale generates an independent score. Validation in Spanish has shown good internal reliability (Cronbach's α \> 0.70 in all three dimensions).

    Time frame: Screening visit.

  5. Assessment of the sociodemographic variable age at the time of the study.

    The sociodemographic variable age will be assessed by calculating the age (in months) from the date of birth to the date of assessment.

    Time frame: Screening visit.

  6. Assessment of the clinical variable number of weekly infusions of clotting factor concentrates at the time of the study.

    The clinical variable number of weekly infusions of clotting factor concentrates will be assessed by calculating the age (in months) from the date of birth to the date of assessment.

    Time frame: Screening visit.

Other outcomes

  1. Assessment of the sociodemographic variable educational level at the time of the study.

    The sociodemographic variable educational level will be assessed using closed-ended questions (primary education / secondary education / university education / postgraduate education).

    Time frame: Screening visit.

  2. Assessment of the sociodemographic variable 'living arrangements at the time of the study'.

    The sociodemographic variable 'living arrangements' will be assessed using a qualitative variable with three response options: alone / with family / with partner.

    Time frame: Screening visit.

  3. Assessment of the clinical variable cohabitation at the time of the study.

    The clinical variable type of hospital where treatment is received will be a dichotomous variable, with two response options: national referral hospital-CESUR / regional referral hospital.

    Time frame: Screening visit.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2025 to primary completion in May 2026, 9 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Sep 2025 → May 2026 and completion Oct 2025 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2025
First posted
Aug 1, 2025
StartActual
Jul 31, 2025
Primary completionActual
May 13, 2026was Sep 2025
CompletionActual
Jun 15, 2026was Oct 2025
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 12, 2026
Primary completion
Sep 13, 2025→May 13, 2026 (actual)
Nov 12, 2026
Study completion
Oct 15, 2025→Jun 15, 2026 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Completed
    Primary completion Sep 13, 2025→May 13, 2026 (now actual)
    Study completion Oct 15, 2025→Jun 15, 2026 (now actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07099313
Lead sponsor
Investigación en Hemofilia y Fisioterapia
Responsible party
Rubén Cuesta-Barriuso (Principal Investigator, Investigación en Hemofilia y Fisioterapia) — Principal investigator
First posted
Aug 1, 2025
Start date
Jul 31, 2025
Primary completion
May 13, 2026
Completion
Jun 15, 2026
Last update
Nov 12, 2026

Study contacts

Rubén Cuesta-Barriuso, PhD
principal investigator · Universidad de Oviedo

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion